FDA Orders New Eye Risk Warnings for Ozempic and Zepbound
People taking popular diabetes and weight-loss medicines may soon see a new warning about a rare eye condition. The US Food and Drug Administration (FDA) is requiring manufacturers of GLP-1 medicines to add information about possible vision loss to their drug labels.
The warning covers medicines such as Ozempic, Wegovy, Mounjaro, and Zepbound. It concerns a condition called non-arteritic anterior ischemic optic neuropathy, commonly known as NAION.
NAION can cause sudden, painless vision loss in one eye. In some people, the damage is permanent.
The FDA says the condition is rare, but its review found enough evidence to require stronger safety information.
What is NAION, and why is the FDA concerned?
NAION happens when blood flow to the front part of the optic nerve becomes reduced. The optic nerve carries visual information from the eye to the brain.
When this nerve does not receive enough blood, it can become damaged. A person may suddenly lose some or much of their vision in one eye.
For example, someone taking Ozempic might wake up and notice that one eye is blurry or has a dark area in its field of vision. They may not feel pain, but the change can still signal an emergency.
The condition can cause permanent vision problems. The FDA says possible symptoms include:
- Sudden, painless vision loss in one eye.
- Blurry or hazy vision.
- Missing areas or blind spots.
- Changes in color vision.
- Reduced sharpness in the center of vision.
Anyone experiencing these symptoms should contact a healthcare professional immediately.
Which weight-loss and diabetes drugs carry the NAION warning?
The FDA's decision applies to all medicines with GLP-1 receptor activity, not just Ozempic and Zepbound.
The affected medicines include:
- Ozempic and Wegovy, which contain semaglutide.
- Mounjaro and Zepbound, which contain tirzepatide.
- Rybelsus, another semaglutide medicine.
- Other medicines in the GLP-1 drug class.
These medicines help manage blood sugar or body weight. Some also have approved benefits for heart disease, kidney disease, and other health conditions.
The FDA is requiring manufacturers to add information about the possible risk of NAION to the warnings and precautions section of their labels.
What evidence links GLP-1 drugs to NAION?
The FDA reviewed clinical trials, animal research, reports of side effects, and observational studies.
Its analysis of 126 clinical trials included more than 134,000 participants. Researchers identified 15 probable NAION cases.
The rate was 6.4 cases per 100,000 person-years among people taking GLP-1 medicines. It was 3.8 cases per 100,000 person-years among people taking comparison treatments.
The FDA also reviewed real-world medical records. One analysis found a higher risk compared with some diabetes medicines, although the results differed depending on which medicines researchers used for comparison.
These findings suggest a possible link, but they do not prove that GLP-1 medicines directly cause NAION.
Other health conditions can also increase the risk. These include diabetes, high blood pressure, smoking, sleep apnea, anemia, and kidney disease.
Should patients stop taking Ozempic or Zepbound?
No. Patients should not stop their medication simply because of the new warning.
GLP-1 medicines can provide important benefits for people managing diabetes, obesity, and certain other conditions. Stopping treatment without medical advice may affect blood sugar control or other health goals.
Anyone who develops sudden vision changes should seek immediate medical attention. If a doctor diagnoses NAION, the patient should discuss whether to stop or continue the medicine.
For example, someone taking Ozempic for type 2 diabetes should not abandon treatment without discussing safer options with their healthcare provider.
You can also read our related articles, New Weight Loss Drug Retatrutide Provides Double the Weight Loss of Ozempic and How Decision Fatigue Affects Diabetes Management (and What to Do About It), for more information about weight-loss medicines and diabetes care.
How can patients protect their eyesight?
Patients taking GLP-1 medicines should be aware of the possible symptoms of NAION. They should also manage health conditions that can affect blood flow and eye health.
Practical steps include:
- Keep blood pressure and blood sugar under control.
- Avoid smoking.
- Attend recommended eye examinations.
- Tell your doctor about existing eye problems.
- Report sudden vision changes immediately.
People who have already experienced NAION in one eye may face a higher risk of developing it in the other eye. They should discuss their medication and eye health with their doctors.
The Bottom Line
The FDA is requiring new NAION warnings for GLP-1 medicines, including Ozempic, Wegovy, Mounjaro, and Zepbound.
The possible eye complication is rare but can cause lasting vision loss. Patients should understand the warning, recognize sudden changes in vision, and discuss concerns with their healthcare providers before changing treatment.
Frequently Asked Questions
Can Ozempic cause blindness?
The FDA has identified a possible link between GLP-1 medicines and NAION, which can cause permanent vision loss. However, the evidence does not prove that Ozempic directly causes the condition.
Is NAION common among people taking weight-loss drugs?
No. The FDA describes NAION as rare. Its clinical trial analysis found 6.4 cases per 100,000 person-years among GLP-1 users.
Should I stop taking Zepbound because of the warning?
Do not stop without speaking to your healthcare provider. Seek immediate medical attention if you experience sudden, painless vision loss or other new vision problems.
